Virchow 2011 or how to ID(H) human glioblastoma

Journal of Clinical Oncology

Volumn 29, Issue 34, 2011, Pages 4473-4474

  De Angelis, Lisa M ^a   Mellinghoff, Ingo K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B; ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; SONIC HEDGEHOG PROTEIN; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; ASTROCYTOMA; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; CPG ISLAND; EDITORIAL; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; GIANT CELL; GLIOBLASTOMA; HUMAN; NECROSIS; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; SECOND CANCER; SOLID TUMOR;

BRAIN NEOPLASMS; CELL LINEAGE; EVOLUTION, MOLECULAR; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE;

EID: 83355169752     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.5873     Document Type: Editorial

References (15)

1. Bailey P, Cushing H: A Classification of the Tumors of the Glioma Group on a Histogenetic Basis with a Correlated Study of Prognosis. Philadelphia, PA, Lippincott, 1926, pp 1-175
2. Scherer HJ: A critical review: The pathology of cerebral gliomas. J Neurol Psychiatry 3:147-177, 1940
3. Scherer HJ: Cerebral astrocytomas and their derivatives. Am J Cancer 40:159-198, 1940
4. Kleihues P, Burger PC, Aldape KD, et al: Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, et al. (eds): WHO Classification of Tumours of the Central Nervous System. Lyon, France, IARC, 2007, pp 33-49
5. Verhaak RG, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
6. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
7. Phillips HS, Kharbanda S, Chen R, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173, 2006 (Pubitemid 43357943)
8. Lai A, Kharbanda S, Pope WB, et al: Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482-4490, 2011
9. Parsons DW, Jones S, Zhang X, et al: An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812, 2008
10. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
11. Sanson M, Marie Y, Paris S, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154, 2009
12. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
13. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009
14. Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-2334, 2011
15. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011